Barclays PLC boosted its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 19.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 254,885 shares of the company's stock after acquiring an additional 40,932 shares during the period. Barclays PLC owned 0.20% of Vaxcyte worth $20,865,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Summit Investment Advisors Inc. boosted its stake in Vaxcyte by 7.5% in the 4th quarter. Summit Investment Advisors Inc. now owns 12,768 shares of the company's stock worth $1,045,000 after purchasing an additional 886 shares in the last quarter. Kennedy Capital Management LLC purchased a new stake in shares of Vaxcyte during the fourth quarter valued at approximately $1,353,000. CenterBook Partners LP purchased a new position in Vaxcyte in the 4th quarter worth approximately $1,913,000. Raymond James Financial Inc. bought a new position in Vaxcyte in the 4th quarter valued at approximately $21,669,000. Finally, Renaissance Technologies LLC purchased a new stake in Vaxcyte during the 4th quarter valued at $4,427,000. Hedge funds and other institutional investors own 96.78% of the company's stock.
Analyst Ratings Changes
A number of research analysts have recently issued reports on PCVX shares. Guggenheim reaffirmed a "buy" rating and set a $160.00 price target on shares of Vaxcyte in a report on Wednesday, March 12th. Bank of America decreased their price objective on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Evercore ISI raised Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. Needham & Company LLC reiterated a "buy" rating and issued a $90.00 price objective on shares of Vaxcyte in a research note on Tuesday, April 8th. Finally, The Goldman Sachs Group cut their target price on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Vaxcyte presently has an average rating of "Buy" and a consensus target price of $136.50.
Read Our Latest Research Report on PCVX
Vaxcyte Stock Performance
Shares of NASDAQ PCVX traded up $1.21 during midday trading on Thursday, reaching $34.37. The stock had a trading volume of 768,273 shares, compared to its average volume of 1,229,810. The company has a market capitalization of $4.43 billion, a price-to-earnings ratio of -7.47 and a beta of 1.26. Vaxcyte, Inc. has a 12-month low of $27.66 and a 12-month high of $121.06. The stock has a 50-day moving average of $57.55 and a 200-day moving average of $81.39.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.14. As a group, analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.
Insider Buying and Selling
In other news, COO Jim Wassil sold 8,000 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $73.27, for a total transaction of $586,160.00. Following the completion of the transaction, the chief operating officer now owns 154,931 shares in the company, valued at $11,351,794.37. This trade represents a 4.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last quarter, insiders sold 24,000 shares of company stock worth $1,946,720. 3.10% of the stock is owned by insiders.
About Vaxcyte
(
Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Featured Articles
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
